Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Xeris Biopharma Holdings, Inc. - Common Stock (NQ:XERS)

8.065 -0.065 (-0.80%)
Streaming Delayed Price Updated: 10:22 AM EST, Jan 9, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Xeris Biopharma Holdings, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
News headline image
Xeris Pharmaceuticals, Inc. to Acquire Strongbridge Biopharma plc in Stock and CVR Transaction, Creating an Innovative Leader in Endocrinology and Rare Diseases
From Xeris Pharmaceuticals, Inc.
Via Business Wire
News headline image
Rule 2.5 Announcement: Xeris Pharmaceuticals, Inc. to Acquire Strongbridge Biopharma Plc in Stock and CVR Transaction, Creating an Innovative Leader in Endocrinology and Rare Diseases
From Xeris Pharmaceuticals, Inc.
Via Business Wire
News headline image
Xeris Pharmaceuticals: Q1 Earnings Insights ↗
Shares of Xeris Pharmaceuticals (NASDAQ:XERS) rose 1.8% in pre-market trading after the company reported Q1 results. Quarterly Results Earnings per share increased 66.29%... 
Via Benzinga
News headline image
Xeris Pharmaceuticals Reports First Quarter 2021 Financial Results and Recent Highlights
From Xeris Pharmaceuticals, Inc.
Via Business Wire
News headline image
Xeris Pharmaceuticals to Webcast Upcoming Presentations
From Xeris Pharmaceuticals, Inc.
Via Business Wire
News headline image
Xeris Pharmaceuticals to Announce First Quarter 2021 Financial Results and Host Conference Call and Webcast on May 13, 2021
From Xeris Pharmaceuticals, Inc.
Via Business Wire
News headline image
Earnings Scheduled For May 13, 2021 ↗
Companies Reporting Before The Bell • CASI Pharmaceuticals (NASDAQ:CASI) is estimated to report quarterly loss at $0.06 per share on revenue of $5.05 million. •... 
Via Benzinga
News headline image
Xeris Pharmaceuticals Announces Extension of the Interest-Only Period of Its Debt Facility With Oxford Finance and Silicon Valley Bank
From Xeris Pharmaceuticals, Inc.
Via Business Wire
News headline image
NASDAQ:XERS Shareholder Notice: Investigation over Potential Wrongdoing at Xeris Pharmaceuticals, Inc. ↗
San Diego, CA -- (SBWIRE) -- 05/05/2021 -- Certain directors of Xeris Pharmaceuticals, Inc. are under investigation over potential breaches of fiduciary duties. 
Via SBWire
News headline image
Xeris Pharmaceuticals Receives U.K. MHRA Approval of Ogluo® (glucagon) Injection for the Treatment of Severe Hypoglycaemia in Adults, Adolescents, and Children Aged 2 Years and Over With Diabetes Mellitus
From Xeris Pharmaceuticals, Inc.
Via Business Wire
News headline image
With a New Diabetes Product Coming to Market, What Lies Ahead for Zealand Pharma Investors? ↗
A new, easier-to-administer treatment for severe hypoglycemia has observers and investors wondering where its creators will go next. 
Via The Motley Fool
News headline image
The Daily Biotech Pulse: Hyperphosphatemia Drug Regulatory Review Extended, Phathom Pharma Data Readout, 2 IPOs ↗
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 29) AtriCure, Inc. (NASDAQ:... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.